FDA warns unapproved morphine makers
While many manufactures may see morphine production restrictions as a legal game of cat and mouse, the FDA begs to differ. Threading legal action to include seizure of all unauthorized drugs and injunction without notice, the FDA is attempting to moderate the production practices of six drug manufactures. Cole Petrochiko, of Medpage Today, recently reminded the online medical new source’s readership of the seriousness of unauthorized production of the morphine drug. The following is an excerpt from Medpage Today of his article:
A new letter issued to Glenmark Generics, Lannett Company, Lehigh Valley Technologies, Mallinckrodt Inc. Pharmaceuticals Group, Boehringer Ingelheim Roxane, and Cody Laboratories offered the companies a reminder that the limitation on their unmoderated production of unapproved morphine sulfate would expire on July 24, 2010.
The letters threatened legal action, including unlimited seizure and injunction and without further notice. The letter also suggested the companies modify their production schedule to assure no surplus of the drug remained once the legal reprieve expired.